Status:
TERMINATED
Furosemide in Early Acute Kidney Injury
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
Austin Hospital, Melbourne Australia
Princess Alexandra Hospital, Brisbane, Australia
Conditions:
Acute Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Acute renal failure, now referred to as acute kidney injury, is common in intensive care unit patients, contributes to high morbidity and mortality, and has no proven interventions with benefit once e...
Detailed Description
Study Design, Setting and Patient Population This is a phase II multi-centre, randomized, blinded, placebo-controlled trial of ICU patients with early AKI with randomization stratified by sepsis. All...
Eligibility Criteria
Inclusion
- Informed and written consent by patient or surrogate
- Peripheral or central intravenous catheter
- The presence of early AKI
- 2 or more criteria for the systemic inflammatory response syndrome (SIRS) within 24 hours
- Achieved immediate resuscitation goals
Exclusion
- Confirmed or suspected pregnancy
- Age \<18 years
- Stage 4 or greater chronic kidney disease or kidney transplantation
- Acute pulmonary edema requiring urgent use of furosemide or RRT
- Patient is moribund with expected death within 24 hours
- Known or suspected drug allergy to furosemide
- Enrolled in concomitant randomized trial
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00978354
Start Date
September 1 2009
End Date
July 1 2014
Last Update
September 30 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Alexandra Hospital
Brisbane, Queensland, Australia, 4012
2
Austin Hospital
Melbourne, Victoria, Australia, 3084
3
General Systems Intensive Care Unit, University of Alberta
Edmonton, Alberta, Canada, T6G2B7
4
University of Laval
Québec, Quebec, Canada, G1V 0A6